Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (1451)	3/18/1998 5:33:00 PM
From: Dan Packer	Read Replies (2) \| Respond to of 5736

Jane, in the FDA filing 78% of the babies were not considered candidates for any bilirubin determination. Another 10% were excluded from the study, so only ~13% of the starting population of newborns were considered candidates for examination. The competing modalities were eyeball comparisons with a color chart. And a plasma colorimeter. First just looks at baby. Second shoves light through baby's blood - and requires a stick. The CCSI gizmo did better. But how much better? Since you are really looking for thresholds, the issue was there a baby who had a toxic, or near toxic level without being captured by the color wheel or the plasma colorimeter? Can you answer that question? ie, What would it cost to prevent one case of kericterus? Color me, Dan